The oncologists will be aware that for those HER2 IHC negative patients with less than 4 tumor fragments, additional biopsies might be needed for further HER2 analysis to avoid missing eligible patients for the molecular-targeted treatment. The gene discussed is ERBB2; the disease is neoplasm.